about
Imputation and subset based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer typesThe second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex diseaseIn Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell typeMetformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drugTreatment of nonmetastatic Ewing's sarcoma family tumors of the spine and sacrum: the experience from a single institution.Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy.Cell growth inhibition and apoptotic effect of the rexinoid 6-OH-11-O-hydroxyphenantrene on human osteosarcoma and mesenchymal stem cells.Generation of human single-chain antibody to the CD99 cell surface determinant specifically recognizing Ewing's sarcoma tumor cells.Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators.CD99 acts as an oncosuppressor in osteosarcomaCD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2.Sortilin regulates progranulin action in castration-resistant prostate cancer cellsAn aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas.Blocking monocyte transmigration in in vitro system by a human antibody scFv anti-CD99. Efficient large scale purification from periplasmic inclusion bodies in E. coli expression system.MiR-187 Targets the Androgen-Regulated Gene ALDH1A3 in Prostate Cancer.Integrated approaches to miRNAs target definition: time-series analysis in an osteosarcoma differentiative model.The expression of ccn3(nov) gene in musculoskeletal tumorsThe metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kitDesign and construction of a new human naïve single-chain fragment variable antibody library, IORISS1.The first European interdisciplinary ewing sarcoma research summitA Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with OsteosarcomaInsulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG statusCaveolins in the development and diseases of musculoskeletal system.Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.Targeted therapies in bone sarcomas.CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling.CD99 polymorphisms significantly influence the probability to develop Ewing sarcoma in earlier age and patient disease progression.Designing novel therapies against sarcomas in the era of personalized medicine and economic crisis.Human myeloma cell lines induce osteoblast downregulation of CD99 which is involved in osteoblast formation and activity.Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor.Process development of a human recombinant diabody expressed in E. coli: engagement of CD99-induced apoptosis for target therapy in Ewing's sarcoma.CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients.ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents.Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma.Characterization of human mesenchymal stem cells from ewing sarcoma patients. Pathogenetic implications.Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells.CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity.
P50
Q23924183-FA1E9E6C-3309-4514-BE9A-468791B24542Q24170413-538EEEEF-2560-45AB-9B45-701E0C6F6176Q26775306-A9D0994A-D9D0-43BD-9DFE-38DDA30FE316Q28244685-E58EB3AC-951F-4B95-95D5-A44D946DA515Q28538155-46553F8F-CBA9-456D-92B0-B53558D6B4BCQ33972685-45E23603-603D-4BAE-A202-C225689782D4Q33985880-D45FF985-8898-492F-9CAE-F3F9586A8DF0Q34067847-8229C11D-FCDF-494D-A8E6-9CEAE8A03DA6Q34159317-EB84B59C-D9BB-44E5-897F-6C7E01208DB8Q34325539-A8089FF6-5067-4375-B5DE-67DB67D76CB0Q34483649-81DB498A-4125-4FE0-ABF7-79C793A8A925Q34629236-59651C29-0273-45AD-B896-6596FDD61990Q34745270-8843AFB0-DDD8-41C9-9778-855351EFBDDDQ35103838-F2AC9F8D-C34E-497B-8C50-EE297E63C235Q35163455-60761D0F-33C3-4923-B33C-C59611892682Q35602182-D11749BC-0BF7-4790-97C0-5C68162CBD79Q35678071-C5CD3C55-5ED7-4285-987B-C5ED57CCBB48Q35788810-70A59E62-2098-4710-A55A-9F8DBC900D6FQ35829711-8AE28574-8912-4F04-9984-18505A6D53B9Q35946569-EC47DD44-7D34-4C1B-B060-0BAF6239717FQ35993560-6DEE6D8B-266C-43CA-91DE-F7D025A17ADBQ36029709-2D89ECA7-B79C-4A6A-8BDF-985D507A48C4Q36381818-CCB0E82F-453F-4030-A4C9-A040A301BBCBQ37432918-1D5CD3B5-894D-4A57-B372-D2DBAEBE152AQ37641721-6EBA6517-F31F-407D-9FFF-7C7A73012BC5Q37660434-05B81255-020E-4F79-B3A9-4422BC52DEB6Q37694869-3C8E651A-629C-4D01-86FE-F64DE9DBF0D8Q37718471-CC3F7998-77D9-4D44-B350-08E0E39F4F9BQ38080104-DCDEDA3C-4A7F-4717-8ED6-46160115DD69Q38298890-3262137E-BE1D-42E0-9029-DAFA1C6C3F0DQ38478426-2273F524-A179-4804-B8EB-85A8A4EB6FC4Q38810472-B77605FC-BF5C-41D6-B290-B31CBBB4DF81Q38830920-59A13C11-B018-44A3-A111-F663D1A98401Q38883101-04DBCEDF-FE97-4723-89E8-5A1A818DE2D8Q38917815-901582EF-3398-4C4E-BCFE-C7976C35CA67Q38929303-557BB54E-9C33-4DCD-A4AB-AD9EAEA5A936Q38950669-053FF889-4747-4082-B33D-4AFE97C9D893Q39026978-DC5226FE-A779-4C6C-AD37-2B27A590049CQ39033443-C4AE1473-F070-486F-BD59-6F80BEA2A228Q39156193-425C2D7E-B255-4A51-B705-4E76E48FA887
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Katia Scotlandi
@ast
Katia Scotlandi
@en
Katia Scotlandi
@es
Katia Scotlandi
@nl
type
label
Katia Scotlandi
@ast
Katia Scotlandi
@en
Katia Scotlandi
@es
Katia Scotlandi
@nl
prefLabel
Katia Scotlandi
@ast
Katia Scotlandi
@en
Katia Scotlandi
@es
Katia Scotlandi
@nl
P106
P21
P31
P496
0000-0001-6114-9499